Genocea Biosciences Inc. Stock
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -3.390% | 0.000% | -0.840% | -43.810% | -43.810% | -10.606% | 120.561% |
| Lexicon Pharmaceuticals Inc. | -3.200% | 4.724% | -15.832% | 40.811% | 40.811% | -40.647% | -62.746% |
| Krystal Biotech | -0.050% | 4.672% | 13.749% | 39.043% | 41.327% | 190.676% | - |
Comments